PureTech made millions on Karuna acquisition. Here’s what it plans to return to shareholders.

On Monday, Bristol Myers Squibb completed its acquisition of Boston drug developer Karuna Therapeutics Inc. for $14 billion. Karuna is a spinout of Boston-based PureTech Health, which will receive hundreds of millions of dollars from its stake in Karuna. Here’s what it plans to do withe the proceeds.

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *